{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Remission&page=20", "query": { "condition": "Remission", "page": 20 }, "page_size": 10 }, "pagination": { "page": 20, "page_size": 10, "total_count": 768, "total_pages": 77, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Remission&page=21&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Remission&page=19&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-25T02:22:23.716Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03114865", "title": "A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia", "B-cell Non Hodgkin Lymphoma", "Pre B-Cell Acute Lymphoblastic Leukaemia" ], "interventions": [ { "name": "Blinatumomab 9ug", "type": "DRUG" }, { "name": "Blinatumomab 28 ug", "type": "DRUG" }, { "name": "Blinatumomab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2017-09-05", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2026-10-22", "last_synced_at": "2026-10-25T02:22:23.716Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03114865" }, { "nct_id": "NCT00896701", "title": "Relationship Between Natural Killer Cells' Ability to Kill Leukemia Cells and the Outcome of Patients With Acute Myeloid Leukemia Previously Treated With Interleukin-2", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Leukemia" ], "interventions": [ { "name": "flow cytometry", "type": "OTHER" }, { "name": "immunologic technique", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 451, "start_date": "2004-01", "completion_date": "2014-04", "has_results": false, "last_update_posted_date": "2016-07-13", "last_synced_at": "2026-10-25T02:22:23.716Z", "location_count": 2, "location_summary": "Kinston, North Carolina • Columbus, Ohio", "locations": [ { "city": "Kinston", "state": "North Carolina" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00896701" }, { "nct_id": "NCT05274230", "title": "Sustaining Remission From PTSD Using Tuned Vibroacoustic Stimulation (TVS) Following MDMA-Assisted Psychotherapy", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Stress Disorders, Post-Traumatic" ], "interventions": [ { "name": "Apollo Wearable", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Apollo Neuroscience, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2021-12-08", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2023-02-02", "last_synced_at": "2026-10-25T02:22:23.716Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05274230" }, { "nct_id": "NCT00104299", "title": "Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Vasculitis", "Wegener's Granulomatosis", "Microscopic Polyangiitis" ], "interventions": [ { "name": "Rituximab plus cyclophosphamide placebo (rituximab group)", "type": "DRUG" }, { "name": "Cyclophosphamide plus rituximab placebo (control group)", "type": "DRUG" }, { "name": "Azathioprine", "type": "DRUG" }, { "name": "Methylprednisolone (or other glucocorticoid)", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 197, "start_date": "2005-01", "completion_date": "2010-01", "has_results": true, "last_update_posted_date": "2017-04-21", "last_synced_at": "2026-10-25T02:22:23.716Z", "location_count": 7, "location_summary": "Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00104299" }, { "nct_id": "NCT03009396", "title": "Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Crohn Disease" ], "interventions": [ { "name": "RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "RedHill Biopharma Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "76 Years", "sex": "ALL", "summary": "18 Years to 76 Years" }, "enrollment_count": 54, "start_date": "2017-03-18", "completion_date": "2019-08-19", "has_results": true, "last_update_posted_date": "2021-02-24", "last_synced_at": "2026-10-25T02:22:23.716Z", "location_count": 6, "location_summary": "San Carlos, California • Marietta, Georgia • Topeka, Kansas + 3 more", "locations": [ { "city": "San Carlos", "state": "California" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Topeka", "state": "Kansas" }, { "city": "Chevy Chase", "state": "Maryland" }, { "city": "Brockton", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03009396" }, { "nct_id": "NCT00281879", "title": "Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Unusual Cancers of Childhood" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "carmustine", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "umbilical cord blood transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "60 Years", "sex": "ALL", "summary": "Up to 60 Years" }, "enrollment_count": 200, "start_date": "2006-02", "completion_date": "2008-03", "has_results": true, "last_update_posted_date": "2017-09-27", "last_synced_at": "2026-10-25T02:22:23.716Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00281879" }, { "nct_id": "NCT01885689", "title": "Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Acute Lymphoblastic Leukemia in Remission", "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome", "Adult Acute Myeloid Leukemia in Remission", "Myelodysplastic Syndrome", "Secondary Myelodysplastic Syndrome", "Chronic Myelomonocytic Leukemia", "Therapy-Related Myelodysplastic Syndrome" ], "interventions": [ { "name": "clofarabine", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "sirolimus", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 72, "start_date": "2014-02-10", "completion_date": "2026-09-21", "has_results": true, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-10-25T02:22:23.716Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01885689" }, { "nct_id": "NCT00313586", "title": "Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11", "Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1", "Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL", "Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA", "Alkylating Agent-Related Acute Myeloid Leukemia", "Chronic Myelomonocytic Leukemia", "de Novo Myelodysplastic Syndrome", "Previously Treated Myelodysplastic Syndrome", "Recurrent Adult Acute Myeloid Leukemia", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndrome", "Untreated Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Entinostat", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 197, "start_date": "2006-08", "completion_date": "2013-07", "has_results": true, "last_update_posted_date": "2017-02-02", "last_synced_at": "2026-10-25T02:22:23.716Z", "location_count": 234, "location_summary": "Scottsdale, Arizona • Burbank, California • Los Angeles, California + 146 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Burbank", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Roseville", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00313586" }, { "nct_id": "NCT00868660", "title": "Healthy Normal Single Ascending Dose and Crohn's Patient Multiple Ascending Dose", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Inflammatory Bowel Disease" ], "interventions": [ { "name": "ZP1848", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Zealand Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 66, "start_date": "2009-01", "completion_date": "2010-02", "has_results": false, "last_update_posted_date": "2010-11-02", "last_synced_at": "2026-10-25T02:22:23.716Z", "location_count": 1, "location_summary": "Willingboro, New Jersey", "locations": [ { "city": "Willingboro", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00868660" }, { "nct_id": "NCT00027820", "title": "Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Acute Myeloid Leukemia in Remission", "Childhood Acute Lymphoblastic Leukemia in Remission", "Childhood Acute Myeloid Leukemia in Remission", "Childhood Myelodysplastic Syndrome", "Childhood Renal Cell Carcinoma", "Chronic Myelomonocytic Leukemia", "Clear Cell Renal Cell Carcinoma", "de Novo Myelodysplastic Syndrome", "Metastatic Renal Cell Cancer", "Previously Treated Myelodysplastic Syndrome", "Progression of Multiple Myeloma or Plasma Cell Leukemia", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult Non-Hodgkin Lymphoma", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Non-Hodgkin Lymphoma", "Refractory Anemia", "Refractory Anemia With Ringed Sideroblasts", "Refractory Childhood Hodgkin Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Renal Medullary Carcinoma", "Type 1 Papillary Renal Cell Carcinoma", "Type 2 Papillary Renal Cell Carcinoma", "Untreated Adult Acute Lymphoblastic Leukemia", "Untreated Adult Acute Myeloid Leukemia", "Untreated Childhood Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Total-Body Irradiation", "type": "RADIATION" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 106, "start_date": "2001-08", "completion_date": "2004-09-05", "has_results": false, "last_update_posted_date": "2019-12-20", "last_synced_at": "2026-10-25T02:22:23.716Z", "location_count": 8, "location_summary": "Tucson, Arizona • Stanford, California • Atlanta, Georgia + 5 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Stanford", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Portland", "state": "Oregon" }, { "city": "Garland", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00027820" } ] }